Skip to main content
. 2016 Dec 31;8(5):8657–8669. doi: 10.18632/oncotarget.14395

Figure 3. Patients with male gender, KPS>80 points, LDH≤216.

Figure 3

5U/L, limited disease and metastatic sites<2 can benefit more from the treatment of thoracic irradiation (p<0.05 on uni- and multivariate analysis). MST, median survival time.